-
公开(公告)号：US11001579B2
公开(公告)日：2021-05-11
申请号：US16438596
申请日：2019-06-12
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/4184 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/14 , C07D471/04 , C07D401/14 , C07D417/12 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04 , A61K31/16 , A61K31/4422 , A61K36/9066
摘要： The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US11066399B2
公开(公告)日：2021-07-20
申请号：US17110465
申请日：2020-12-03
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/14 , C07D471/04 , C07D401/14 , C07D417/12 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04 , A61K31/4184 , A61K31/16 , A61K31/4422 , A61K36/9066
摘要： The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US10364239B2
公开(公告)日：2019-07-30
申请号：US15769148
申请日：2016-10-21
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/4184 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/12 , C07D417/14 , C07D471/04 , C07D401/14 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04 , A61K31/16 , A61K31/4422 , A61K36/9066
摘要： The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20180319783A1
公开(公告)日：2018-11-08
申请号：US15769148
申请日：2016-10-21
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , C07D417/14 , C07D417/12 , C07D413/04 , C07D401/14 , C07D403/14 , C07D471/04 , C07D487/04 , A61P25/16 , A61P25/28 , A61P3/12 , A61P7/06
CPC分类号： C07D413/14 , A61K31/16 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4422 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K36/9066 , A61K45/06 , A61K2300/00 , A61P3/12 , A61P7/06 , A61P25/16 , A61P25/28 , C07D277/56 , C07D401/14 , C07D403/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/411
摘要： The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20180297991A1
公开(公告)日：2018-10-18
申请号：US15768025
申请日：2016-10-21
发明人： Franz Dürrenberger , Wilm Buhr , Susanna Burckhardt , Michael Burgert , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D417/12 , C07D417/14 , C07D471/04 , C07D277/56 , C07D413/14 , C07D401/14 , A61K31/427 , A61K31/4439 , A61K31/4725 , A61K31/5377 , A61K31/4709 , A61K31/435 , A61K31/506 , A61K31/497 , A61K31/4375 , A61K31/437 , A61K31/426 , A61K45/06
摘要： The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20220363675A1
公开(公告)日：2022-11-17
申请号：US17340692
申请日：2021-06-07
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/4184 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/14 , C07D471/04 , C07D401/14 , C07D417/12 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04
摘要： The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US10738041B2
公开(公告)日：2020-08-11
申请号：US15768025
申请日：2016-10-21
发明人： Franz Dürrenberger , Wilm Buhr , Susanna Burckhardt , Michael Burgert , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/427 , A61K31/437 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/55 , C07D417/12 , C07D471/04 , C07D401/14 , A61K31/426 , A61K31/435 , A61K31/497 , A61K45/06 , C07D277/56 , C07D403/14 , C07D413/04 , C07D487/04 , A61K31/4184 , A61K31/4355 , A61K31/4375 , A61K31/4439 , A61K31/4985 , A61K31/5377 , C07D417/14 , A61K31/4709 , A61K31/4725 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , A61K31/16 , A61K31/4422 , A61K36/9066
摘要： The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.056 秒)
